Comments on: Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy

Comments on: Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy https://www.novumpr.nl/2016/11/07/english-only-biogen-and-ionis-pharmaceuticals-announce-spinraza-nusinersen-meets-primary-endpoint-at-interim-analysis-of-phase-3-cherish-study-in-later-onset-spinal-muscular-atrophy/?utm_source=rss&utm_medium=rss&utm_campaign=english-only-biogen-and-ionis-pharmaceuticals-announce-spinraza-nusinersen-meets-primary-endpoint-at-interim-analysis-of-phase-3-cherish-study-in-later-onset-spinal-muscular-atrophy NovumPR press releases Mon, 07 Nov 2016 13:05:15 +0000 hourly 1 https://wordpress.org/?v=6.8.3